Vikram Verghese Sells 27,540 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFLGet Free Report) CFO Vikram Verghese sold 27,540 shares of Heartflow stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $49.69, for a total transaction of $1,368,462.60. Following the sale, the chief financial officer owned 221,143 shares of the company’s stock, valued at approximately $10,988,595.67. The trade was a 11.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

  • On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The stock was sold at an average price of $50.60, for a total transaction of $297,325.60.

Heartflow Stock Performance

Heartflow stock opened at $48.91 on Friday. The firm’s fifty day moving average price is $33.76 and its 200-day moving average price is $29.92. The stock has a market cap of $4.25 billion and a P/E ratio of -26.73. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.78.

Heartflow (NASDAQ:HTFLGet Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company’s revenue was up 47.7% compared to the same quarter last year. On average, analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current year.

Institutional Investors Weigh In On Heartflow

A number of hedge funds and other institutional investors have recently modified their holdings of HTFL. Vanguard Group Inc. bought a new position in Heartflow during the 3rd quarter worth approximately $48,871,000. Legal & General Group Plc bought a new stake in Heartflow in the third quarter valued at approximately $59,000. Franklin Resources Inc. purchased a new stake in shares of Heartflow during the third quarter valued at approximately $10,829,000. UBS Group AG bought a new position in shares of Heartflow in the third quarter worth approximately $5,130,000. Finally, Sei Investments Co. bought a new position in shares of Heartflow in the third quarter worth approximately $303,000.

Wall Street Analysts Forecast Growth

HTFL has been the topic of a number of research reports. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a research note on Friday, August 14th. JPMorgan Chase & Co. increased their price target on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Piper Sandler restated an “overweight” rating and issued a $45.00 price objective (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. Finally, Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Heartflow currently has an average rating of “Moderate Buy” and an average target price of $43.43.

Get Our Latest Analysis on HTFL

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

Featured Articles

Insider Buying and Selling by Quarter for Heartflow (NASDAQ:HTFL)

Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.